Morgan Stanley’s enGene Therapeutics ENGN Stock Holding History

Morgan Stanley’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$590K	Sell	86,600 -631,885	-88%	-$5.63M	﹤0.01%	5407
2025 Q4	$6.49M	Buy	718,485 +283,194	+65%	+$2.27M	﹤0.01%	3980
2025 Q3	$2.97M	Buy	435,291 +82,523	+23%	+$376K	﹤0.01%	4533
2025 Q2	$1.28M	Sell	352,768 -83,796	-19%	-$314K	﹤0.01%	4979
2025 Q1	$1.96M	Sell	436,564 -2,208	-0.5%	-$13.7K	﹤0.01%	4614
2024 Q4	$2.92M	Buy	438,772 +430,579	+5,255%	+$3.34M	﹤0.01%	4425
2024 Q3	$54.1K	Buy	8,193 +8,135	+14,026%	+$60.5K	﹤0.01%	6196
2024 Q2	$547	Buy	58 +50	+625%	+$641	﹤0.01%	7220
2024 Q1	$136	Sell	8 -8	-50%	-$98	﹤0.01%	7345
2023 Q4	$148	Buy	+16	New	+$142	﹤0.01%	7388

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Morgan Stanley's ENGN Position: Q1 2026 in Review

Morgan Stanley reduced its enGene Therapeutics (ENGN) stake by 88% in Q1 2026, selling an estimated $5.63M and leaving 86,600 shares worth $590K. The position accounts for ﹤0.01% of the portfolio, ranked #5407.

Morgan Stanley first reported a position in ENGN in Q4 2023 and has held it in 10 quarters since. The position peaked at $6.49M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

Morgan Stanley held 86,600 shares of enGene Therapeutics worth $590K as of Q1 2026.
Morgan Stanley sold 631,885 enGene Therapeutics shares in Q1 2026, an estimated $5.63M.
enGene Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5407 holding.
Morgan Stanley first reported a position in enGene Therapeutics in Q4 2023 and has held it in 10 quarters since.
Morgan Stanley's enGene Therapeutics position peaked at $6.49M in Q4 2025.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.